Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772989 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
A Phase 1 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT04772989: Completed Phase 1 study, sponsored by Arcus Biosciences.
NCT04772989 is a Phase 1 study that has completed, run by Arcus Biosciences. The registered enrollment target is 94 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04772989, a Phase 1 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
Interventions
- DRUG Zimberelimab
- DRUG AB308
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2025-08-25 |
| Phase | Phase 1 |
What the finished NCT04772989 record still lists
NCT04772989 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher).
The record links to 0 conditions, and to 2 interventions - of which Zimberelimab is the first listed.
NCT04772989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04772989 about?
NCT04772989 is a clinical study titled "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies". This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
What is the current status of trial NCT04772989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2021-03-19. Estimated completion is 2025-08-25.
What interventions are being tested in trial NCT04772989?
The interventions under investigation include: Zimberelimab (DRUG), AB308 (DRUG).
Who is sponsoring clinical trial NCT04772989?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04772989's enrollment target sits among peer trials
94 615th of 2000 higher than 1,377 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI